{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T03:12:51Z","timestamp":1778901171715,"version":"3.51.4"},"reference-count":28,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2027,4,28]],"date-time":"2027-04-28T00:00:00Z","timestamp":1808870400000},"content-version":"am","delay-in-days":392,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["UG1CA233180"],"award-info":[{"award-number":["UG1CA233180"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000892","name":"Prostate Cancer Foundation","doi-asserted-by":"publisher","award":["17CHAL04"],"award-info":[{"award-number":["17CHAL04"]}],"id":[{"id":"10.13039\/100000892","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100011541","name":"National Cancer Institute Division of Cancer Epidemiology and Genetics","doi-asserted-by":"publisher","award":["UG1CA189859"],"award-info":[{"award-number":["UG1CA189859"]}],"id":[{"id":"10.13039\/100011541","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100011541","name":"National Cancer Institute Division of Cancer Epidemiology and Genetics","doi-asserted-by":"publisher","award":["UG1CA233320"],"award-info":[{"award-number":["UG1CA233320"]}],"id":[{"id":"10.13039\/100011541","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100011541","name":"National Cancer Institute Division of Cancer Epidemiology and Genetics","doi-asserted-by":"publisher","award":["UG1CA233234"],"award-info":[{"award-number":["UG1CA233234"]}],"id":[{"id":"10.13039\/100011541","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100011541","name":"National Cancer Institute Division of Cancer Epidemiology and Genetics","doi-asserted-by":"publisher","award":["UG1CA189828"],"award-info":[{"award-number":["UG1CA189828"]}],"id":[{"id":"10.13039\/100011541","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100011541","name":"National Cancer Institute Division of Cancer Epidemiology and Genetics","doi-asserted-by":"publisher","award":["UG1CA233196"],"award-info":[{"award-number":["UG1CA233196"]}],"id":[{"id":"10.13039\/100011541","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100011541","name":"National Cancer Institute Division of Cancer Epidemiology and Genetics","doi-asserted-by":"publisher","award":["UG1CA233277"],"award-info":[{"award-number":["UG1CA233277"]}],"id":[{"id":"10.13039\/100011541","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100011541","name":"National Cancer Institute Division of Cancer Epidemiology and Genetics","doi-asserted-by":"publisher","award":["UG1CA233290"],"award-info":[{"award-number":["UG1CA233290"]}],"id":[{"id":"10.13039\/100011541","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100011541","name":"National Cancer Institute Division of Cancer Epidemiology and Genetics","doi-asserted-by":"publisher","award":["U10CA180794"],"award-info":[{"award-number":["U10CA180794"]}],"id":[{"id":"10.13039\/100011541","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100011541","name":"National Cancer Institute Division of Cancer Epidemiology and Genetics","doi-asserted-by":"publisher","award":["U10CA180820"],"award-info":[{"award-number":["U10CA180820"]}],"id":[{"id":"10.13039\/100011541","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","euoncology.europeanurology.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Urology Oncology"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1016\/j.euo.2025.04.003","type":"journal-article","created":{"date-parts":[[2025,4,16]],"date-time":"2025-04-16T16:34:15Z","timestamp":1744821255000},"page":"268-275","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Genetic Drivers of Quality of Life in Prostate Cancer: An Evaluation of Genetic Polymorphisms and Patient-reported Outcomes in the E3805 CHAARTED trial"],"prefix":"10.1016","volume":"9","author":[{"given":"Daniel","family":"Sentana-Lledo","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiangying","family":"Chu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Charles J.","family":"Ryan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arjun","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christopher J.","family":"Sweeney","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David F.","family":"Jarrard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elizabeth R.","family":"Plimack","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Benjamin A.","family":"Gartrell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael A.","family":"Carducci","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maha","family":"Hussain","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jorge A.","family":"Garcia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Cella","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert S.","family":"DiPaola","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark","family":"Pomerantz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alicia K.","family":"Morgans","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.euo.2025.04.003_b0005","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/j.molmed.2015.02.009","article-title":"Genetics and the placebo effect: the placebome","volume":"21","author":"Hall","year":"2015","journal-title":"Trends Mol Med"},{"key":"10.1016\/j.euo.2025.04.003_b0010","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1097\/00008571-199606000-00007","article-title":"Human catechol-O-methyltransferase pharmacogenetics: description of a functional polymorphism and its potential application to neuropsychiatric disorders","volume":"6","author":"Lachman","year":"1996","journal-title":"Pharmacogenet Genomics"},{"key":"10.1016\/j.euo.2025.04.003_b0015","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1038\/nn1438","article-title":"Midbrain dopamine and prefrontal function in humans: interaction and modulation by COMT genotype","volume":"8","author":"Meyer-Lindenberg","year":"2005","journal-title":"Nat Neurosci"},{"key":"10.1016\/j.euo.2025.04.003_b0020","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1080\/03602532.2016.1258075","article-title":"The Val158Met polymorphism in COMT gene and cancer risk: role of endogenous and exogenous catechols","volume":"29","author":"Sak","year":"2017","journal-title":"Drug Metab Rev"},{"key":"10.1016\/j.euo.2025.04.003_b0025","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1136\/bmj.39524.439618.25","article-title":"Components of placebo effect: randomised controlled trial in patients with irritable bowel syndrome","volume":"336","author":"Kaptchuk","year":"2008","journal-title":"BMJ"},{"key":"10.1016\/j.euo.2025.04.003_b0030","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1097\/FPC.0b013e328337f9ab","article-title":"Effect of catechol-O-methyltransferase polymorphism on response to propranolol therapy in chronic musculoskeletal pain: a randomized, double\u2013blind, placebo-controlled, crossover pilot study","volume":"20","author":"Tchivileva","year":"2010","journal-title":"Pharmacogenet Genomics"},{"key":"10.1016\/j.euo.2025.04.003_b0035","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1016\/S0006-3223(99)00098-0","article-title":"Global variation in the frequencies of functionally different catechol-O-methyltransferase alleles","volume":"46","author":"Palmatier","year":"1999","journal-title":"Biol Psychiatry"},{"key":"10.1016\/j.euo.2025.04.003_b0040","doi-asserted-by":"crossref","first-page":"4890","DOI":"10.1158\/1078-0432.CCR-15-2823","article-title":"Pharmacogenetic discovery in CALGB (Alliance) 90401 and mechanistic validation of a VAC14 polymorphism that increases risk of docetaxel-induced neuropathy","volume":"22","author":"Hertz","year":"2016","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.euo.2025.04.003_b0045","doi-asserted-by":"crossref","first-page":"e1173","DOI":"10.1016\/j.clbc.2018.04.018","article-title":"Association of allelic interaction of single nucleotide polymorphisms of influx and efflux transporters genes with nonhematologic adverse events of docetaxel in breast cancer patients","volume":"18","author":"Jabir","year":"2018","journal-title":"Clin Breast Cancer"},{"key":"10.1016\/j.euo.2025.04.003_b0050","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.critrevonc.2017.11.012","article-title":"A review of the literature on the relationships between genetic polymorphisms and chemotherapy-induced nausea and vomiting","volume":"121","author":"Singh","year":"2018","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1016\/j.euo.2025.04.003_b0055","doi-asserted-by":"crossref","first-page":"4543","DOI":"10.1158\/1078-0432.CCR-07-4230","article-title":"ABCB1 genetic variation influences the toxicity and clinical outcome of patients with androgen-independent prostate cancer treated with docetaxel","volume":"14","author":"Sissung","year":"2008","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.euo.2025.04.003_b0060","doi-asserted-by":"crossref","first-page":"5082","DOI":"10.1158\/1078-0432.CCR-15-0586","article-title":"Genome-wide association studies for taxane-induced peripheral neuropathy in ECOG-5103 and ECOG-1199","volume":"21","author":"Schneider","year":"2015","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.euo.2025.04.003_b0065","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1200\/JCO.2017.75.3657","article-title":"Chemohormonal therapy in metastatic hormone-sensitive prostate cancer: long-term survival analysis of the randomized phase III E3805 CHAARTED trial","volume":"36","author":"Kyriakopoulos","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.euo.2025.04.003_b0070","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1200\/JCO.2017.75.3335","article-title":"Quality of life during treatment with chemohormonal therapy: analysis of E3805 chemohormonal androgen ablation randomized trial in prostate cancer","volume":"36","author":"Morgans","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.euo.2025.04.003_b0075","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1056\/NEJMoa1503747","article-title":"Chemohormonal therapy in metastatic hormone-sensitive prostate cancer","volume":"373","author":"Sweeney","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.euo.2025.04.003_b0080","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.euo.2024.04.010","article-title":"Patient-reported quality of life and survival outcomes in prostate cancer: analysis of the ECOG-ACRIN E3805 Chemohormonal Androgen Ablation Randomized Trial (CHAARTED)","volume":"8","author":"Sentana-Lledo","year":"2025","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.euo.2025.04.003_b0085","unstructured":"R Core Team. The R project for statistical computing. https:\/\/www.r-project.org\/."},{"key":"10.1016\/j.euo.2025.04.003_b0090","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1200\/JCO.2014.60.2557","article-title":"Prostate cancer survivorship care guideline: American Society of Clinical Oncology clinical practice guideline endorsement","volume":"33","author":"Resnick","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.euo.2025.04.003_b0095","first-page":"225","article-title":"American Cancer Society prostate cancer survivorship care guidelines","volume":"64","author":"Skolarus","year":"2014","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.euo.2025.04.003_b0100","article-title":"Symptom burden and survivorship care for patients with prostate cancer on androgen deprivation therapy","volume":"23","author":"Sentana-Lledo","year":"2025","journal-title":"J Natl Compr Cancer Netw"},{"key":"10.1016\/j.euo.2025.04.003_b0105","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.urolonc.2019.10.006","article-title":"Improving research for prostate cancer survivorship: a statement from the Survivorship Research in Prostate Cancer (SuRECaP) working group","volume":"38","author":"Narayan","year":"2020","journal-title":"Urol Oncol"},{"key":"10.1016\/j.euo.2025.04.003_b0110","doi-asserted-by":"crossref","first-page":"529","DOI":"10.2217\/pgs-2019-0001","article-title":"Systems pharmacogenomics \u2013 gene, disease, drug and placebo interactions: a case study in COMT","volume":"20","author":"Hall","year":"2019","journal-title":"Pharmacogenomics"},{"key":"10.1016\/j.euo.2025.04.003_b0115","doi-asserted-by":"crossref","DOI":"10.1093\/ijnp\/pyv132","article-title":"Catechol-o-methyltransferase Val158Met polymorphism and clinical response to antipsychotic treatment in schizophrenia and schizo-affective disorder patients: a meta-analysis","volume":"19","author":"Huang","year":"2016","journal-title":"Int J Neuropsychopharmacol"},{"key":"10.1016\/j.euo.2025.04.003_b0120","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.pain.2005.03.032","article-title":"The Val158Met polymorphism of the human catechol-O-methyltransferase (COMT) gene may influence morphine requirements in cancer pain patients","volume":"116","author":"Rakv\u00e5g","year":"2005","journal-title":"Pain"},{"key":"10.1016\/j.euo.2025.04.003_b0125","doi-asserted-by":"crossref","DOI":"10.1155\/2024\/9990112","article-title":"The catechol-o-methyltransferase (COMT) Val158Met polymorphism is associated with oxycodone requirements, adverse effects, and pain sensitivity in cancer patients","volume":"2024","author":"Xu","year":"2024","journal-title":"J Clin Pharm Ther"},{"key":"10.1016\/j.euo.2025.04.003_b0130","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1007\/s10549-011-1757-y","article-title":"Catechol-O-methyltransferase genotype (Val158met) modulates cancer-related fatigue and pain sensitivity in breast cancer survivors","volume":"133","author":"Fern\u00e1ndez-de-las-Pe\u00f1as","year":"2012","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.euo.2025.04.003_b0135","doi-asserted-by":"crossref","first-page":"3207","DOI":"10.3390\/cancers14133207","article-title":"Testing for dihydropyrimidine dehydrogenase deficiency to individualize 5-fluorouracil therapy","volume":"14","author":"Diasio","year":"2022","journal-title":"Cancers"},{"key":"10.1016\/j.euo.2025.04.003_b0140","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1200\/OP.21.00624","article-title":"All you need to know about UGT1A1 genetic testing for patients treated with irinotecan: a practitioner-friendly guide","volume":"18","author":"Karas","year":"2022","journal-title":"JCO Oncol Pract"}],"container-title":["European Urology Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2588931125000896?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2588931125000896?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T02:35:35Z","timestamp":1778898935000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2588931125000896"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":28,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["S2588931125000896"],"URL":"https:\/\/doi.org\/10.1016\/j.euo.2025.04.003","relation":{},"ISSN":["2588-9311"],"issn-type":[{"value":"2588-9311","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Genetic Drivers of Quality of Life in Prostate Cancer: An Evaluation of Genetic Polymorphisms and Patient-reported Outcomes in the E3805 CHAARTED trial","name":"articletitle","label":"Article Title"},{"value":"European Urology Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.euo.2025.04.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 European Association of Urology. Published by Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}